Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Combinatorial treatments targeting MAPK and PI3K/mTOR pathways in metastatic melanoma
PubMed Full text in PMC Similar studies Analyze with GEO2R
Expression data from exponentially proliferating ovarian cancer cell lines
Antitumor efficacy of RAF inhibitor GDC-0879 involving BRAFV600E mutational status and ERK/MAPK pathway suppression
PubMed Similar studies Analyze with GEO2R
Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour
Expression data from BRAF-mutant melanoma cell lines
Molecular changes induced in melanoma cells by stromal cells and anti-BRAF therapy.
PI3K/AKT/mTOR and Sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth
Human BRAF-V600E melanoma cell lines drug sensitive vs drug resistant
Acquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Pan-Raf co-operates with PI3K-dependent signaling and critically contributes to myeloma cell survival independently of mutated RAS
Expression of BRAF inhibitor resistant colon cancer lines
Colon cancer cell lines with acquired resistance to BRAF inhibitor
PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet
protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]
protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309
Targeting the MTOR-AKT pathway in DLBCL
Rapamycin-resistant diffuse large B-cell lymphoma cell lines
Predominance of MAPK reactivation in early resistance to debrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma.
Role of Apollon in human melanoma resistance to anti-tumor agents that activate the intrinsic or the extrinsic apoptosis pathways
Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma.
Exosome-mediated interaction in the tumor microenvironment modulates MIR211 response via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on